{"id":"doi:10.1186/s12943-019-1057-4","kind":"review","title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","authors":["Yu S","Yi M","Qin S","Wu K"],"author_count":4,"year":2019,"published":"2019-08-20","venue":"Molecular cancer","cited_by":226,"doi":"10.1186/s12943-019-1057-4","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s12943-019-1057-4","archive_url":"https://space-kitty.com/papers/doi:10.1186/s12943-019-1057-4","updated":null,"pmid":"31429760","pmcid":"PMC6701025","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC6701025/pdf","abstract":"Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved exciting results. Two Anti-CD19 CAR-T therapies have been approved for the treatment of CD19-positive leukemia or lymphoma. However, the application of CAR-T cells is obviously hampered by the adverse effects, such as cytokines release syndrome and on-target off-tumor toxicity. In some clinical trials, patients quitted the treatment of CAR-T cells due to life-threatening toxicity. Seeking to alleviate these toxicities or prevent the occurrence, researchers have developed a number of safety strategies of CAR-T cells, including suicide genes, synthetic Notch receptor, on-switch CAR, combinatorial target-antigen recognition, bispecific T cell engager and inhibitory CAR. This review summarized the preclinical studies and clinical trials of the safety strategies of CAR-T cells and their respective strengths and weaknesses.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity\" by Yu S, Yi M, Qin S et al., https://doi.org/10.1186/s12943-019-1057-4, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}